Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple Sponsors
- 24 June 2009
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 86 (6) , 619-625
Abstract
This study, conducted under the Metabolic Disorders Steering Committee of the Biomarkers Consortium (a public-private partnership managed by the Foundation for the National Institutes of Health (FNIH)), analyzed blinded data on 2,688 type 2 diabetes (T2D) patients from randomized clinical trials conducted by four pharmaceutical companies. An increase in the levels of adiponectin was observed after peroxisome proliferator-activated receptor (PPAR)-agonist treatment (P < 0.0001), but not after treatment with non-PPAR drugs. This increase correlated with decreases in levels of glucose, hemoglobin A(1c) (Hb(A1c)), hematocrit, and triglycerides, and increases in levels of blood urea nitrogen, creatinine, and high-density lipoprotein cholesterol (HDL-C). Early (6-8 weeks) increases in levels of adiponectin after treatment with PPAR agonists showed a negative correlation (r = -0.21, P < 0.0001) with subsequent changes in levels of Hb(A1c). Changes in adiponectin level did not appear to be associated with baseline level of Hb(A1c). Logistic regression demonstrated that an increase in the level of adiponectin predicts a decrease in the level of Hb(A1c). These analyses confirm previously demonstrated relationships between adiponectin levels and metabolic parameters and support the robust predictive utility of adiponectin across the spectrum of glucose tolerance. Cross-company precompetitive collaboration is a feasible and powerful approach to biomarker qualification.Keywords
This publication has 22 references indexed in Scilit:
- Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention ProgramDiabetes, 2008
- Effects of Peroxisome Proliferator-Activated Receptor-Gamma Activation With Pioglitazone on Plasma Adipokines in Nondiabetic Patients With Either Hypercholesterolemia or HypertensionThe American Journal of Cardiology, 2008
- Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetesDiabetes & Vascular Disease Research, 2007
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2007
- Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin SensitivityJournal of Biological Chemistry, 2004
- The central role of fat and effect of peroxisome proliferator-activated receptor–γ on progression of insulin resistance and cardiovascular diseaseThe American Journal of Cardiology, 2003
- Glitazones: clinical effects and molecular mechanismsAnnals of Medicine, 2002
- Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPAR Agonists: A Potential Mechanism of Insulin SensitizationEndocrinology, 2002
- The PPARs: From Orphan Receptors to Drug DiscoveryJournal of Medicinal Chemistry, 2000